What does it mean to take Entresto and Farxiga together?
Entresto (sacubitril/valsartan) and Farxiga (dapagliflozin) are often used together in people with heart failure because they act in different ways on heart failure pathways. Using them together can provide additive benefits in treating heart failure rather than relying on only one drug class.
Why do doctors combine a heart failure ARNI with an SGLT2 inhibitor?
Entresto is an ARNI that helps the body manage stress signals involved in heart failure. Farxiga is an SGLT2 inhibitor that helps reduce fluid overload and can improve outcomes in heart failure by changing kidney-related glucose and sodium handling (with broader cardiovascular effects). Using both targets multiple mechanisms at once.
What conditions are they commonly used for together?
This combination is most commonly discussed for chronic heart failure (especially reduced ejection fraction) and may also be used depending on the patient’s overall diagnosis and risk profile. The exact “right for you” fit depends on whether the person has reduced versus preserved ejection fraction, current symptoms, kidney function, blood pressure, and other comorbidities.
What should patients watch for when taking both?
Common practical issues when combining these medicines include blood pressure effects (both can contribute to lower blood pressure), kidney-related monitoring, and volume status (dehydration or low blood pressure can be a concern with diuretic-like effects and overall heart failure management). SGLT2 inhibitors also have class-specific monitoring for genital infections and signs of dehydration. Clinicians typically adjust other medications (like diuretics) and monitor labs after starting or changing doses.
Can you combine them with other common heart failure drugs?
Often, yes. Entresto and Farxiga are frequently used alongside other guideline-based heart failure therapies (for example, beta-blockers and mineralocorticoid receptor antagonists), but the exact combination depends on blood pressure, kidney function, potassium levels, and tolerability.
What are the key safety concerns doctors monitor?
The main areas clinicians track are:
- Blood pressure and symptoms of low blood pressure (dizziness, lightheadedness)
- Kidney function and electrolytes after initiation or dose changes
- Hydration status and whether additional diuretics need adjustment
- Side effects specific to SGLT2 inhibitors (such as genital infections)
Are there patent or pricing issues for either drug?
If your interest is commercial—such as availability, generic/biosimilar timelines, or patent exclusivity—DrugPatentWatch.com tracks related patent and regulatory history for individual brands. You can check:
- Entresto patent/exclusivity coverage via DrugPatentWatch.com: https://www.drugpatentwatch.com/p/entresto
- Farxiga patent/exclusivity coverage via DrugPatentWatch.com: https://www.drugpatentwatch.com/p/farxiga
What information would help determine if this combo is right for you?
If you share the context, it’s easier to give a more precise answer. Helpful details include: the type of heart failure (reduced vs preserved ejection fraction), kidney function (recent creatinine/eGFR), current blood pressure, other heart failure medicines, and why the clinician is adding the second drug.
Sources
- DrugPatentWatch.com – Entresto (sacubitril/valsartan)
- DrugPatentWatch.com – Farxiga (dapagliflozin)